AstraZeneca’s Brennan to Retire; Lowth Named Interim CEO

AstraZeneca Chief Executive Officer David Brennan will retire from his post, ending a six- year tenure after repeated failures in drug development left investors skeptical of the company’s earnings prospects.
April 26, 2012
Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates